⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577443 | 0.58 | — | — | |
| SCHEMBL24815387 | 0.55 | NOTUM (0.38) | — | |
| SCHEMBL22099773 | 0.54 | — | — | |
| SCHEMBL9903249 | 0.53 | — | — | |
| SCHEMBL9902635 | 0.49 | — | — | |
| SCHEMBL1034170 | 0.45 | — | — | |
| SCHEMBL7939995 | 0.43 | — | — | |
| Chloropentafluoroethane SCHEMBL29031907 | 0.41 | LMNA (0.33) | — | |
| Phosphine SCHEMBL27868470 | 0.41 | — | — | |
| Chloropentafluoroethane SCHEMBL341488 | 0.41 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | claimed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | claimed |
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | claimed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2417134-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | claimed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-10654830-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190055221-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-5470867-A | Imidazoles and their salts having antagonistic activity to angiotesin II recetors | ROUSSEL-UCLAF (FR) | 1995-11-28 | — | — | US | disclosed |
| US-5389634-A | Treating arterial hypertension, relaxing uterus, prevention of post-angioplastic restenosis | ROUSSEL-UCLAF (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5338756-A | Angiotensin II receptor antagonists | ROUSSEL UCLAF (FR) | 1994-08-16 | — | — | US | disclosed |
| EP-0461040-A1 | Imidazol derivatives, their process for production, intermediates, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1991-12-11 | — | — | EP | disclosed |